Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades.
Category: Immunotherapy
-
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs
The New York Times – Business: -
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
The New York Times – Business:In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
-
FDA OKs New Keytruda Shot for Cancer
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and increase costs by billions of dollars.
-
The Medicine Is a Miracle, but Only if You Can Afford It
The New York Times – Business:A wave of new treatments have cured devastating diseases. When the costs are too much, even for the insured, patients hunt for other ways to pay.